(Press-News.org) BOSTON, MA—Blood hormone tests can predict a woman's risk for developing postmenopausal breast cancer for up to 20 years, according to a study led by Xuehong Zhang, MD, Channing Division of Network Medicine, Brigham and Women's Hospital (BWH) Department of Medicine.
The findings will be presented at the 11th Annual American Association for Cancer Research (AACR) International Conference on Frontiers in Cancer Prevention Research.
Using data from the Nurses' Health Study, Zhang , Susan Hankinson, ScD, Channing Division of Network Medicine, BWH Department of Medicine and colleagues analyzed 796 patients with postmenopausal breast cancer who had not received hormone therapy.
They conducted blood hormone tests at two time points: between 1989 and 1990 and between 2000 and 2002. Researchers matched each patient with two controls who were not diagnosed with breast cancer.
"We found that a single hormone level was associated with breast cancer risk for at least 16 to 20 years among postmenopausal women not using postmenopausal hormones," said Zhang. "We, and others, are now evaluating if the addition of hormone levels to current risk prediction models can substantially improve our ability to identify high-risk women who would benefit from enhanced screening or chemoprevention—if so, the current data suggest that hormone levels would not need to be measured in the clinic more than once every 10, or possibly 20, years."
Women with hormone levels in the highest 25 percent for estradiol, testosterone and DHEAS had a 50 percent to 107 percent greater chance for developing breast cancer compared with women in the lowest 25 percent. Relative risks for developing breast cancer were similar at one to 10 years vs. 11 to 20 years (also 16 to 20 years) after blood collection.
Researchers also investigated whether these higher levels were more closely linked to hormone-receptor positive breast cancers and if they predicted risk regardless of tumor aggressiveness.
In the first case, they found that elevated levels of estradiol increase a woman's risk for hormone receptor-positive breast cancer, specifically estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) tumors.
In general, increased hormone levels, except for DHEAS, tracked closely with increased risk for receptor-positive breast cancer. Data on receptor-negative cancers were inconclusive and need additional, large studies.
Significantly, elevated hormone levels were also associated with aggressive breast cancer, which the study defined as recurrent or fatal cancer.
"The relationship was comparable or possibly stronger for recurrent and fatal breast cancer than it was for overall breast cancer risk although these results were based on relative small numbers of participants," said Zhang.
###
Researchers also confirmed the protective effect of sex hormone-binding globulin (SHBG), which seems to negate the cancer-causing effects of certain hormones. Women in the highest 25 percent of SHBG levels had a 30 percent lower risk for breast cancer compared with women in the lowest 25 percent for SHBG levels.
Zhang noted that the study had low case numbers for several cancer subgroups, including HER2, triple-negative and basal-like breast cancers. More research is necessary to determine the relationship between elevated hormone levels and these important breast cancer groups.
This research was supported by the National Institutes of Health (CA49449 and CA87969).
This press release was adapted from the American Association for Cancer Research.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving nearly 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $625 million in funding. BWH continually pushes the boundaries of medicine, including building on its legacy in organ transplantation by performing the first face transplants in the U.S. in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies, OurGenes and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.
Blood hormone levels can predict long-term breast cancer risk
2012-10-19
ELSE PRESS RELEASES FROM THIS DATE:
Living in ethnically homogenous area boosts health of minority seniors
2012-10-19
An African-American or Mexican-American senior living in a community where many neighbors share their background is less likely to have cancer or heart disease than their counterpart in a more mixed neighborhood.
Results of the new study by Kimberly Alvarez, a PhD student at Columbia University's Mailman School of Public Health, and Becca Levy, PhD, associate professor of Epidemiology and Psychology at the Yale School of Public Health, appear in the December issue of the American Journal of Public Health and online.
Counter to prevailing notions, researchers found ...
Stroke patients benefit from carmaker's efficiency
2012-10-19
A process developed to increase efficiency and productivity in Japanese car factories has helped improve stroke treatment at Barnes-Jewish Hospital, report researchers at Washington University School of Medicine in St. Louis.
By applying the principles of Toyota's lean manufacturing process, doctors sharply reduced the average time between patient arrival and treatment, known as door-to-needle time, from 58 to 37 minutes.
The findings are reported Oct. 18 in the journal Stroke. In an average year, the medical school's physicians treat 1,300 stroke patients at Barnes-Jewish.
Beginning ...
No antibodies, no problem
2012-10-19
Researchers at the Johns Hopkins Bloomberg School of Public Health have determined a new mechanism by which the mosquitoes' immune system can respond with specificity to infections with various pathogens, including the parasite that causes malaria in humans, using one single gene. Unlike humans and other animals, insects do not make antibodies to target specific infections. According to the Johns Hopkins researchers, mosquitoes use a mechanism known as alternative splicing to arrange different combinations of binding domains, encoded by the same AgDscam gene, into protein ...
Study shows breastfeeding reduced risk for ER/PR-negative breast cancer
2012-10-19
October 18, 2012 -- Breast-feeding reduces the risk for estrogen receptor-negative and progesterone receptor-negative breast cancer, according to a study conducted at Columbia University's Mailman School of Public Health. Researchers examined the association between reproductive risk factors — such as the number of children a woman delivers, breast-feeding and oral contraceptive use – and found an increased risk for estrogen receptor- and progesterone receptor- (ER/PR) negative breast cancer in women who do not breast-feed. The results also indicated that having three ...
Study shows elevated risk of blood clots in women taking birth control containing drospirenone
2012-10-19
OAKLAND, Calif., Oct. 18— A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) — commonly referred to as blockage of arteries and blood clots, respectively — associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives.
The study appears in the current online issue of Contraception.
"We found that starting use of drospirenone-containing combined ...
Caltech modeling feat sheds light on protein channel's function
2012-10-19
PASADENA, Calif.—Chemists at the California Institute of Technology (Caltech) have managed, for the first time, to simulate the biological function of a channel called the Sec translocon, which allows specific proteins to pass through membranes. The feat required bridging timescales from the realm of nanoseconds all the way up to full minutes, exceeding the scope of earlier simulation efforts by more than six orders of magnitude. The result is a detailed molecular understanding of how the translocon works.
Modeling behavior across very different timescales is a major ...
Depression, shortened telomeres increase mortality in bladder cancer patients
2012-10-19
HOUSTON - Low depressive symptoms and a longer telomere length are compelling factors that contribute to a prolonged life for bladder cancer patients according to researchers at The University of Texas MD Anderson Cancer Center.
In an observational study, a team of MD Anderson researchers analyzed clinical and behavioral data collected from 464 bladder cancer patients, according to research presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research.
"This is the first study of its kind that analyzes bladder cancer outcomes," ...
Bicycle infrastructure can reduce risk of cycling injuries by half: UBC study
2012-10-19
Certain types of routes carry much lower risk of injury for cyclists, according to a new University of British Columbia study on the eve of Vancouver's Bike to Work Week.
The study, published today in the American Journal of Public Health, analyzed the cause of 690 cycling injuries in Vancouver and Toronto from 2008 to 2009 and various route types and infrastructure.
The greatest risk to cyclists occurs when they share major streets with parked cars, with no bike lanes present – like on Broadway in Vancouver or Dundas Street in Toronto. Without a designated space on ...
AMP reports on possibilities, challenges, and applications of next-generation sequencing
2012-10-19
Bethesda, MD, October 18, 2012 The Association for Molecular Pathology (AMP) published the
report of the Whole Genome Analysis (WGA) Working Group of the AMP Clinical Practice Committee
in the November 2012 issue of The Journal of Molecular Diagnostics (JMD). Titled "Opportunities and
Challenges Associated with Clinical Diagnostic Genome Sequencing," the timely report provides a
detailed and compelling overview of the landscape of next generation sequencing (NGS) technology
and its clinical relevance and impact on improving patient care. The issues addressed in the ...
First-of-its-kind self-assembled nanoparticle for targeted and triggered thermo-chemotherapy
2012-10-19
Boston, MA— Excitement around the potential for targeted nanoparticles (NPs) that can be controlled by stimulus outside of the body for cancer therapy has been growing over the past few years. More specifically, there has been considerable attention around near-infrared (NIR) light as an ideal method to stimulate nanoparticles from outside the body. NIR is minimally absorbed by skin and tissue, has the ability to penetrate deep tissue in a noninvasive way and the energy from NIR light can be converted to heat by gold nanomaterials for effective thermal ablation of diseased ...